An observational study in Hereditary Angioedema, sponsored by KalVista Pharmaceuticals, Ltd.. Completed at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by KalVista Pharmaceuticals, Ltd. (part of Chiesi Farmaceutici S.p.A.) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A. — 1 open to participants now, 1 under way, none of them phase 3. Angioedemas, Hereditary · Chiesi Farmaceutici S.p.A..
Among the 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A., this one is the only one that started in 2025, is the only observational one, and was the 10th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →1 of the 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A. is open now, in 1 country. Recruiting first, the newest first:
KalVista Pharmaceuticals, Ltd. · Sites in United States
Ages 12+
By country, each count listing its studies:
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 88 is below the median of 100 across 43 observational studies indexed under Angioedemas, Hereditary.
Median enrollment 84 across the 9 interventional studies, 88 across the 1 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under KalVista Pharmaceuticals, Ltd., one of the names counted as Chiesi Farmaceutici S.p.A.. Under that name alone:
KalVista Pharmaceuticals, Ltd. is the lead sponsor of 15 studies on the registry; 2 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.
1 of the studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07654829KalVista Pharmaceuticals, Ltd.Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL) | 2027-11-29 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patients with HAE Type I or II who enroll in the study are asked to complete a patient diary when they experience an HAE attack. If icatibant is taken as the first treatment for the attack, the patient diary will ask questions over a 48 hour period after dosing to track the characteristics and severity of the attack along with the patient's level of anxiety.
Patients with a self-reported diagnosis of HAE Type I or II who take icatibant to treat HAE attacks
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Inapplicable
Inapplicable
Patient Global Impression of Change (PGI-C)
time to beginning of symptom relief defined as at least ''a little better'' (2 time points in a row)
Time frame: Within 12 hours of the first Icatibant dose adminstration
Patient Global Impression of Severity (PGI-S)
Time to first incidence of decrease from baseline (2 time points in a row)
Time frame: Within 12 hours of the first Icatibant dose adminstration
PGI-S: Time to Complete HAE Attack Resolution
time to HAE attack resolution, defined as ''none''
Time frame: Within 24 hours of the first Icatibant dose adminstration
Return to normal function
Time to return to normal daily activities. Date/Time or one of the following options: * Not Applicable - daily activities were not affected * not yet returned to normal activities
Time frame: At 48 hours after first Icatibant dose adminstration
General Anxiety Numeric Rating Scale (GA-NRS): Cumulative GA-NRS
Patient is asked 'How anxious do you feel right now?' 11-point numeric scale, 0-10 with 0=Not at all anxious and 10=Extremely anxious
Time frame: over 12 and 24 hours of the first icatibant administration
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing but only after deidentification of individual patient data.
No publications or documents are linked to this record.
Ran from Apr 2025 to primary completion in Nov 2025, 7 months.
Of 27 observational studies under Angioedemas, Hereditary, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 52. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
KalVista Pharmaceuticals, Ltd. →